24 Jan 2014
The European Medicines Agency did not issue a positive opinion on Novartis' relaxin-based heart failure drug Serelaxin at a recent meeting. Novartis has responded to affirm that they will reapply once the results of another ongoing trial are available.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024